Biblio

Author Title Type [ Year(Asc)]
Filters: First Letter Of Title is O  [Clear All Filters]
2019
Pereira, A.R., Trivanovic, D., and Herrmann, M. (2019). Osteoarthritis as an organ disease: from the cradle to the graveApproaches to mimic the complexity of the skeletal mesenchymal stem/stromal cell niche in vitro.Eur Cell Mater37, 88-112.
Bourebaba, L., Röcken, M., and Marycz, K. (2019). Osteochondritis dissecans (OCD) in Horses - Molecular Background of its Pathogenesis and Perspectives for Progenitor Stem Cell Therapy.Stem Cell Rev.
Sari, D.Sandra, Maduratna, E., Latief, F.Dzar Eljab, Nugraha, A.Patera, Sudiana, K., and Rantam, F.Abdul (2019). Osteogenic Differentiation and Biocompatibility of Bovine Teeth Scaffold with Rat Adipose-derived Mesenchymal Stem Cells.Eur J Dent.
Rumiński, S., Kalaszczyńska, I., Długosz, A., and Lewandowska-Szumieł, M. (2019). Osteogenic differentiation of human adipose-derived stem cells in 3D conditions - comparison of spheroids and polystyrene scaffolds.Eur Cell Mater37, 382-401.
Westhauser, F., Karadjian, M., Essers, C., Senger, A.-S., Hagmann, S., Schmidmaier, G., and Moghaddam, A. (2019). Osteogenic differentiation of mesenchymal stem cells is enhanced in a 45S5-supplemented β-TCP composite scaffold: an in-vitro comparison of Vitoss and Vitoss BA.Plos One14, e0212799.
Srinaath, N., Balagangadharan, K., Pooja, V., Paarkavi, U., Trishla, A., and Selvamurugan, N. (2019). Osteogenic potential of zingerone, a phenolic compound in mouse mesenchymal stem cells.Biofactors.
Shanmugam, H., V Dharun, N., Biswal, B.Kumar, S Chandran, V., Vairamani, M., and Selvamurugan, N. (2019). Osteogenic stimulatory effect of heraclenin purified from bael in mouse mesenchymal stem cells in vitro.Chem Biol Interact108750.
Liu, C., and Sun, J. (2019). Osteogenically differentiated mesenchymal stem cells induced by hydrolyzed fish collagen maintain their immunomodulatory effects.Life Sci116970.
Alam, M., Bertolini, M., Gherardini, J., Keren, A., Ponce, L., Chéret, J., Alenfall, J., Dunér, P., Nilsson, A.H., Gilhar, A., et al. (2019). An osteopontin-derived peptide inhibits human hair growth at least in part by decreasing FGF7 production in outer root sheath keratinocytes.Br J Dermatol.
Wålinder, G., Samuelsson, J., Näsman, P., Hansson, M., Juliusson, G., Forsberg, K., Svensson, R., Linder, O., Carlson, K., Kristinsson, S.Y., et al. (2019). Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry.Eur J Haematol.
Ringdén, O., Boumendil, A., Labopin, M., Canaani, J., Beelen, D., Ehninger, G., Niederwieser, D., Finke, J., Stelljes, M., Gerbitz, A., et al. (2019). OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT.Biol Blood Marrow Transplant.
Candoni, A., Rambaldi, A., Fanin, R., Velardi, A., Arcese, W., Ciceri, F., Lazzarotto, D., Lussana, F., Olivieri, J., Grillo, G., et al. (2019). Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Societ.Biol Blood Marrow Transplant.
Chaudhry, Q.Un Nisa, Iftikhar, R., Satti, T.Mehmood, Mahmood, S.Kamran, Ghafoor, T., Shamshad, G.Umair, Shahbaz, N., Khan, M.Ali, Khattak, T.Azam, Rehman, J., et al. (2019). Outcome of Fludarabine Based Conditioning in High Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single Center Study from Pakistan.Biol Blood Marrow Transplant.
Shah, K., and Sumer, H. (2019). Outcome of safety and efficacy of allogeneic mesenchymal stromal cell derived from umbilical cord for the treatment of osteoarthritis in a randomized blinded placebo-controlled trial.Ann Transl Med7, S154.
Hill-Kayser, C.E., Tochner, Z., Li, Y., Kurtz, G., Lustig, R.A., James, P., Balamuth, N., Womer, R., Mattei, P., Grupp, S., et al. (2019). Outcomes after Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma.Int J Radiat Oncol Biol Phys.
Marks, D.I., Kebriaei, P., Stelljes, M., Gökbuget, N., Kantarjian, H., Advani, A.S., Merchant, A., Stock, W., Cassaday, R.D., Wang, T., et al. (2019). Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia.Biol Blood Marrow Transplant.
Sanders, S., Chua, N., Larouche, J.-F., Owen, C., Shafey, M., and Stewart, D.A. (2019). Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplant-Eligible Patients.Biol Blood Marrow Transplant.
Shah, G., Mikhail, F.M., Bachiasvilli, K., Vachhani, P., Erba, H.P., and Papadantonakis, N. (2019). Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase.Hematol Oncol Stem Cell Ther.
Halder, R., Mishra, P., Dhawan, R., Aggarwal, M., Seth, T., Mahapatra, M., and Saxena, R. (2019). Outcomes of paroxysmal nocturnal hemoglobinuria in the pediatric age group in a resource-constrained setting.Pediatr Blood Cancere27712.
Malenda, A., Kołkowska-Leśniak, A., Puła, B., Długosz-Danecka, M., Chełstowska, M., Końska, A., Giza, A., Lech-Maranda, E., Jurczak, W., and Warzocha, K. (2019). Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma.Eur J Haematol.
Lammert, J., Skandarajah, A.R., Shackleton, K., Calder, P., Thomas, S., Lindeman, G.J., and Mann, G.Bruce (2019). Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience.Asia Pac J Clin Oncol.
Hatina, J., Boesch, M., Sopper, S., Kripnerova, M., Wolf, D., Reimer, D., Marth, C., and Zeimet, A.G. (2019). Ovarian Cancer Stem Cell Heterogeneity.Adv Exp Med Biol1139, 201-221.
Su, Y.-K., Bamodu, O.Adebayo, Tzeng, Y.-M., Hsiao, M., Yeh, C.-T., and Lin, C.-M. (2019). Ovatodiolide inhibits the oncogenicity and cancer stem cell-like phenotype of glioblastoma cells, as well as potentiate the anticancer effect of temozolomide.Phytomedicine61, 152840.
Xiang, J., Ding, Y., Li, J., Zhao, X., Sun, Y., Wang, D., Wang, L., and Chen, Y. (2019). Ovatodiolides: Scalable Protection-free Syntheses, Configuration Determination and Biological Evaluation against Hepatic Cancer Stem Cells.Angew Chem Int Ed Engl.
Kawai, H., Matsushita, H., Suzuki, R., Kitamura, Y., Ogawa, Y., Kawada, H., and Ando, K. (2019). Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein.Neoplasia21, 788-801.

Pages